Nutrimax 12 Weeks

Adult dosage

Adults: Administer intravenously as a maximum dose of 1-1.5 g of total amino acids per day per kg of body weight. Typically, this medication is administered as a single dose of 200 mL (equivalent to 22.7 g of total amino acids) via intravenous drip. Administration rate: This medication is based on 120 minutes for 200 mL. When utilized for central venous infusion, this medication should be infused continuously with dextrose or other sugar solutions for 24 hours.

This medication must be used strictly according to the doctor's instructions. It should not be used in patients who are allergic to any component of this medicine or in those with hepatic coma or those at risk of such a condition. Patients with severe renal impairment or azotemia should also avoid using this medication, as well as patients with amino acid metabolism disorders or those suffering from wasting congestive heart failure, pulmonary edema, oliguria, or anuria. In cases where sodium or chloride-containing components are included, this medication should not be used in patients with hypernatremia, hyperchloremia, alkalosis, over-hydration, or a history of myocardial infarction. Caution is required when administering this medication to patients with severe acidosis, congestive heart failure, severe renal impairment receiving dialysis or blood filtration, those retaining sodium with edema, or patients with liver or kidney disorders. This medication contains sodium bisulfite, which can cause allergic reactions to sulfites, and may particularly provoke asthma attacks in asthmatic patients, thus caution is necessary. While administering this medication, adverse reactions such as nausea, vomiting, abdominal bloating, rash, elevated blood pressure, palpitations, phlebitis, chills, and fever may occur; therefore, if such symptoms arise, medical staff should be informed immediately. In patients with severely decreased renal function, the decision to administer should be made after checking the condition through blood tests and fluid balance evaluation. Women who are pregnant or of childbearing potential should carefully consider the risks and benefits of administering this medication and should avoid it while breastfeeding or discontinue breastfeeding if necessary. Safety in children has not been sufficiently established, and elderly individuals should have their dosing rate slowed and doses adjusted due to decreased bodily functions. This medication should be stored protected from direct sunlight at room temperature, and should not be used if the contents are contaminated or the packaging is damaged. It should be warmed to body temperature during administration and used immediately after opening, with any leftover medication being discarded. Additionally, it should be slowly administered intravenously, and electrolyte balance should also be carefully monitored.

Serious side effects

Severe allergic reactions (hives, severe swelling, chest tightness, breathing difficulties, cold sweat, pallor), asthma attacks, respiratory distress, severe renal impairment, urinary abnormalities and severe edema due to azotemia, liver dysfunction (jaundice), severe neurological symptoms (headache, seizures, confusion), severe edema or urinary abnormalities.

Mild side effects

• Hypersensitivity
• rash
• erythema
• nausea
• vomiting
• abdominal bloating
• changes in bowel movement
• discomfort in the chest
• palpitations
• elevated blood pressure

This medication should be stored in a sealed container to avoid exposure to air and is safely stored at room temperature between 1 and 30 degrees Celsius. Therefore, it is important to avoid areas that are too hot or too cold and to maintain an appropriate temperature.

Appearance

A colorless to light yellow transparent liquid contained in a colorless transparent glass vial for injection.

Package unit

10 vials/box [200 mL/vial]